Other News To Note
Friday, March 18, 2011
TaiMed Biologics Inc., of Taipei, Taiwan, and Ambrilia Biopharma Inc., of Montreal, inked an agreement under which TaiMed will acquire exclusive worldwide rights to manufacture, develop and commercialize both protease inhibitor and integrase inhibitor programs for HIV. Under the terms, Ambrilia will get $250,000 up front and could receive up to an additional $7.6 million in development, regulatory and sales milestones, plus tiered royalties on worldwide product sales.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.